The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer (CIN3+)

We analysed DNA methylation at >850,000 CpG sites across the genome using the Illumina EPIC array in a total of 1,254 cervical liquid-based cytology samples from cases of screen-detected histologically verified CIN1-3+ (98% hrHPV-positive) and population-based control women free from any cervical disease (100% hrHPV-positive). We developed the WID-CIN-test which is a DNA methylation signature consisting of 5,000 CpG sites.

Type: Other
Archiver: European Genome-Phenome Archive (EGA)

4 Datasets 2 Publications

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00010002068	Raw methylation from cervical samples of controls (both HPV+ and HPV-)	Illumina MethylationEPIC Array	527
EGAD00010002069	Raw methylation from cervical samples of individuals who did not develop CIN.	Illumina MethylationEPIC Array	218
EGAD00010002070	Raw methylation from cervical samples of cases (CIN1-3+)	Illumina MethylationEPIC Array	513
EGAD00010002071	Raw methylation from cervical samples of individuals who developed CIN 1-4 years after sampling.	Illumina MethylationEPIC Array	226

Publications	Citations
The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer. Barrett JE, Sundström K, Jones A, Evans I, Wang J, Herzog C, Dillner J, Widschwendter M. Genome Med 14: 2022 116	4
DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN test. Herzog C, Sundström K, Jones A, Evans I, Barrett JE, Wang J, Redl E, Schreiberhuber L, Costas L, Paytubi S, Dostalek L, Zikan M, Cibula D, Sroczynski G, Siebert U, Dillner J, Widschwendter M. Clin Epigenetics 14: 2022 150	2